Access now available for eligible HER2-positive metastatic patients
OTTAWA, Nov. 2, 2011 /CNW/ - The Canadian Breast Cancer Network (CBCN)
commends the Ontario government's decision to fund Herceptin in the
second-line setting for women with HER2-positive metastatic breast
Until now, patients who responded well to initial treatment of Herceptin
when first diagnosed have been denied access to the same treatment
following disease progression. Yesterday's decision will enable many
women whose breast cancer has progressed to receive Herceptin in the
second line setting, offering them a chance to extend their lives.
CBCN has been working with patients to advocate for access to standard
of care across Canada. The organization has also heard from many other
Canadians who have offered their support and time to help fight for
these women to have a second chance using this lifesaving drug.
"We want to thank the Ontario government for looking into the evidence
and making this important decision, which offers tremendous hope for so
many women fighting metastatic HER2-positive breast cancer," says
Cathy Ammendolea, chair of CBCN. "We would also like to thank our
members for actively embracing this issue. It's incredible to see the
amount of support that exists within the breast cancer community."
While fewer patients relapse due to the success of Herceptin in earlier
stages of breast cancer, an unmet medical need has continued to exist
for metastatic patients requiring the treatment beyond the first-line
Ontario joins British Columbia and Saskatchewan in approving funding for
Herceptin for HER2-positive metastatic breast cancer patients who have
been previously treated with it.
HER2-positive breast cancer is an aggressive form of the disease that
affects 20 to 25 per cent of patients.
SOURCE Canadian Breast Cancer Network (CBCN)
For further information:
Ashley Mac Isaac-Butler
Government Relations & Policy Manager
Canadian Breast Cancer Network